The third quarter report of 2023 shows the important role of medical technology in promoting high-quality diagnostic services. In this stage of continuous transformation and upgrading, quality and efficiency improvement of the biomedical industry, Jinyu Testing has not only maintained steady growth in the routine medical testing business, but also made remarkable progress in a number of key disease areas.
In the first three quarters, Jinyu Testing's revenue reached 63100 million yuan, and the net profit attributable to the parent company reached 57.6 billion yuan, of which the revenue of routine medical testing services dominated, reaching 589.1 billion yuan, a year-on-year increase of 1665%。This achievement is due to the company's nationwide multi-center layout and continuous innovation and service network in key detection technologies for rare diseases.
Significant progress has been made in a number of areas
Jinyu Testing has performed well in key disease areas, and its infectious disease diagnosis business has grown by 513%, while genetic and rare diseases, neurological and psychiatric diseases, and cardiovascular and endocrine disease diagnoses also increased, respectively. 36%。The company's independent innovation in these fields has launched special projects such as upgraded RNA-Seq detection, tumor whole transcriptome (WTS) sequencing detection, and Alzheimer's disease early screening detection, which have been widely recognized by clinical practice.
Jinyu Testing is also further optimizing the customer structure, and the proportion of hospital revenue has increased to 4265%, an increase of 5 year-on-year87 percentage points. This optimization has been a driver of business growth and has made the company's business growth more sustainable.
Driven by scientific and technological innovationThe digital transformation has achieved remarkable results
Jinyu Testing adheres to scientific and technological innovation, and has developed more than 300 new projects, with a total of more than 3,900 testing items, covering the diversified clinical needs of accurate diagnosis. At the same time, the company continues to carry out joint scientific and technological research projects with large tertiary hospitals or scientific research institutes, and has established more than 180 partners. Through these cooperation, Jinyu Testing has launched leading technologies such as CAR-T** whole-process management testing projects.
In terms of digital transformation, Jinyu Testing actively explores the field of smart medical examination. By initiating the digital transformation work, Jinyu Testing has created a "medical examination 4The "0" platform, including intelligent recommendation, smart laboratory, AI pathology, clinical auxiliary diagnosis, etc., has initially shown results.
In the future, Jinyu Testing will continue to adhere to innovation leadership, transform more innovative achievements into practical results that can be implemented, promoted and valuable, and continue to inject impetus into the high-quality development of the industry. In the context of the continuous integration of biotechnology and a new generation of information technology, Jinyu Testing is expected to bring more innovations and breakthroughs to the field of medical diagnostic services.